Literature DB >> 10411844

Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock.

D Morales1, J Madigan, S Cullinane, J Chen, M Heath, M Oz, J A Oliver, D W Landry.   

Abstract

BACKGROUND: Hypovolemic shock of marked severity and duration may progress to cardiovascular collapse unresponsive to volume replacement and drug intervention. On the basis of clinical observations, we investigated the action of vasopressin in an animal model of this condition. METHODS AND
RESULTS: In 7 dogs, prolonged hemorrhagic shock (mean arterial pressure [MAP] of approximately 40 mm Hg) was induced by exsanguination into a reservoir. After approximately 30 minutes, progressive reinfusion was needed to maintain MAP at approximately 40 mm Hg, and by approximately 1 hour, despite complete restoration of blood volume, the administration of norepinephrine approximately 3 micrograms . kg(-1). min(-1) was required to maintain this pressure. At this moment, administration of vasopressin 1 to 4 mU. kg(-1). min(-1) increased MAP from 39+/-6 to 128+/-9 mm Hg (P<0.001), primarily because of peripheral vasoconstriction. In 3 dogs subjected to similar prolonged hemorrhagic shock, angiotensin II 180 ng. kg(-1). min(-1) had only a marginal effect on MAP (45+/-12 to 49+/-15 mm Hg). Plasma vasopressin was markedly elevated during acute hemorrhage but fell from 319+/-66 to 29+/-9 pg/mL before administration of vasopressin (P<0.01).
CONCLUSIONS: Vasopressin is a uniquely effective pressor in the irreversible phase of hemorrhagic shock unresponsive to volume replacement and catecholamine vasopressors. Vasopressin deficiency may contribute to the pathogenesis of this condition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411844     DOI: 10.1161/01.cir.100.3.226

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

1.  Impact of low-dose vasopressin on trauma outcome: prospective randomized study.

Authors:  Stephen M Cohn; Janet McCarthy; Ronald M Stewart; Rachelle B Jonas; Daniel L Dent; Joel E Michalek
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

2.  Multiple alpha1-adrenergic receptor subtypes support synergistic stimulation of vasopressin and oxytocin release by ATP and phenylephrine.

Authors:  Zhilin Song; Dayane A Gomes; Wanida Stevens; Celia D Sladek
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-09-29       Impact factor: 3.619

Review 3.  [Treatment of hemorrhagic shock. New therapy options].

Authors:  W G Voelckel; A von Goedecke; D Fries; A C Krismer; V Wenzel; K H Lindner
Journal:  Anaesthesist       Date:  2004-12       Impact factor: 1.041

4.  [Vasopressin].

Authors:  W Schummer; C Schummer; J Fuchs
Journal:  Anaesthesist       Date:  2005-07       Impact factor: 1.041

5.  Augmented central nitric oxide production inhibits vasopressin release during hemorrhage in acute alcohol-intoxicated rodents.

Authors:  Annie M Whitaker; Jesse K Sulzer; Patricia E Molina
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-17       Impact factor: 3.619

6.  New trends in resuscitation.

Authors:  Hasan B Alam; George C Velmahos
Journal:  Curr Probl Surg       Date:  2011-08       Impact factor: 1.909

Review 7.  Helping prometheus: liver protection in acute hemorrhagic shock.

Authors:  Nils T Veith; Tina Histing; Michael D Menger; Tim Pohlemann; Thomas Tschernig
Journal:  Ann Transl Med       Date:  2017-05

8.  Effect of Low-Dose Supplementation of Arginine Vasopressin on Need for Blood Product Transfusions in Patients With Trauma and Hemorrhagic Shock: A Randomized Clinical Trial.

Authors:  Carrie A Sims; Daniel Holena; Patrick Kim; Jose Pascual; Brian Smith; Neils Martin; Mark Seamon; Adam Shiroff; Shariq Raza; Lewis Kaplan; Elena Grill; Nicole Zimmerman; Christopher Mason; Benjamin Abella; Patrick Reilly
Journal:  JAMA Surg       Date:  2019-11-01       Impact factor: 14.766

Review 9.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Surface-enhanced Raman spectroscopy based quantitative bioassay on aptamer-functionalized nanopillars using large-area Raman mapping.

Authors:  Jaeyoung Yang; Mirko Palla; Filippo Giacomo Bosco; Tomas Rindzevicius; Tommy Sonne Alstrøm; Michael Stenbæk Schmidt; Anja Boisen; Jingyue Ju; Qiao Lin
Journal:  ACS Nano       Date:  2013-06-07       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.